NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a randomized, double-blind study in Obesity Surgery ...
In a new phase 3, double-blind study, researchers explored the efficacy and safety of combination therapy using subcutaneous (SC) belimumab and rituximab for the treatment of active systemic lupus ...
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...
Objectives To investigate if daily treatment with glyceryl trinitrate (GTN) ointment, over 24 weeks combined with a 12-week eccentric exercise programme is more effective for chronic mid-portion ...
Medical research shapes healthcare every day, but not all studies are created equal. Knowing the differences can help you feel more confident reading health information online and understanding what ...
“Can the blind lead the blind? Shall they not both fall into the pit?” Luke 6:39 While “the blind leading the blind” has become an often-used idiom of incompetency and ineffectiveness, the “randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results